Richard Harrigan

prharrigan@cfenet.ubc.ca
Lab Website: http://www.cfenet.ubc.ca/our-work/programs/laboratory-program

Current Positions

  • Associate Professor, Division of AIDS, Medicine
  • Director, Laboratory Program, British Columbia Centre for Excellence in HIV/AIDS
  • Glen-Hillson Professor in Clinical HIV Virology, The University of British Columbia
  • CIHR/GSK Research Chair in HIV/AIDS at the University of British Columbia

Research Interests

The primary goal of the basic research program is to provide novel virological and drug information for HIV-infected British Columbians receiving antiretroviral therapy. Key priorities include understanding and preventing HIV drug resistance, the development, application and evaluation of innovative cost-effective laboratory tests that monitor HIV therapy response and antiretroviral drug toxicities, improving drug adherence through the development and application of laboratory-based tools that accurately detect and report non-adherence, investigation of the relationships between human and viral genetic factors and treatment outcomes, and therapeutic drug monitoring. The research laboratory team includes individuals with expertise in virology, genomics, chemistry, molecular biology and quality assurance systems.

Selected Publications

  1. Rocheleau G, Brumme CJ, Shoveller J, Lima VD, Harrigan PR. Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016. Clinical Microbiology and Infection. 2018 February;24(2):185-191. SA
  2. Jacka B, Bray B, Applegate T, Marshall B, Dias Lima V, Hayashi K, DeBeck K, Raghwani J, Harrigan PR, Krajden M, Montaner JS, Grebely J. Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach. Journal of Viral Hepatitis. 2018 January;25(1):28-36. CA
  3. Jones BR, Howe AYM, Harrigan PR, Joy JB. The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus. Virus Evolution. 2018 January 16;4(1):vex041. CA
  4. Noguera-Julian M, Edgil D, Harrigan PR, Sandstrom P, Godfrey C, Paredes R. Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance. The Journal of Infectious Diseases. 2017 December 1;216(suppl_9):S829-S833. CA
  5. Hashemi P, Barreto K, Bernhard W, Lomness A, Honson N, Pfeifer TA, Harrigan PR, Sadowski I. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency. EMBO Molecular Medicine. 2017 Dec 15. [Epub ahead of print]. CA
  6. Harris M, Ganase B, Watson B, Harrigan PR, Montaner JSG, Hull MW. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study. AIDS Research and Therapy. 2017 November 2;14(1):59. CA
  7. Lee GQ, Bangsberg DR, Mo T, Lachowski C, Brumme CJ, Zhang W, Lima VD, Boum Y 2nd, Mwebesa BB, Muzoora C, Andia I, Mbalibulha Y, Kembabazi A, Carroll R, Siedner MJ, Haberer JE, Mocello AR, Kigozi SH, Hunt PW, Martin JN, Harrigan PR. Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches. AIDS. 2017 November 13;31(17):2345-2354. SA
  8. Lee G, McCluskey S, Boum Y, Hunt P, Martin J, Bangsberg, Gao X, Harrigan PR, Haberer J, Siedner M. Brief Report: Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes. 2017 October 1;76(2):188-192. CA
  9. Gonzalez-Serna A, Ajaykumar A, Gadawski I, Muñoz-Fernández MA, Hayashi K, Harrigan PR, Côté HCF. Rapid Decrease in Peripheral Blood Mononucleated Cell Telomere Length After HIV Seroconversion, but Not HCV Seroconversion. Journal of Acquired Immune Deficiency Syndromes. 2017 September 1;76(1):e29-e32. CA
  10. Socías M, Nosova E, Kerr T, Hayashi K, Harrigan PR, Shoveller J, Montaner JS, Milloy MJ. Patterns of transmitted drug resistance and virological response to first-line antiretroviral treatment among HIV-positive people who use illicit drugs in a Canadian setting. Clinical Infectious Diseases. 2017 September 1;65(5):796-802. CA
  11. Boucoiran I, Albert AYK, Tulloch K, Wagner EC, Pick N, van Schalkwyk J, Harrigan PR, Money D. Human Immunodeficiency Virus Viral Load Rebound Near Delivery in Previously Suppressed, Combination Antiretroviral Therapy-Treated Pregnant Women. Obstetrics & Gynecology. 2017 September;130(3):497-501. CA
  12. Olding M, Enns B, Panagiotoglou D, Shoveller J, Harrigan PR, Barrios R, Kerr T, Montaner JSG, Nosyk B. A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015. Journal of the International AIDS Society. 2017 September 19;20(1):21941. CA
  13. Rocheleau G, Franco-Villalobos C, Oliveira N, Brumme ZL, Rusch M, Shoveller J, Brumme CJ, Harrigan PR. Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada. PLoS One. 2017 September 22;12(9):e0184848. CA
  14. Engels EA, Yanik EL, Wheeler W, Gill MJ, Shiels MS, Dubrow R, Althoff KN, Silverberg MJ, Brooks JT, Kitahata MM, Goedert JJ, Grover S, Mayor AM, Moore RD, Park LS, Rachlis A, Sigel K, Sterling TR, Thorne JE, Pfeiffer RM; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clinical Infectious Diseases. 2017 August 15;65(4):636-643. CA
  15. Nosyk B, Zang X, Min J, Krebs E, Lima V, Milloy M-J, Shoveller J, Barrios R, Harrigan PR, Kerr T, Wood E, Montaner JS. Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996–2013: a modelling study. Lancet HIV. 2017 July;4(7):e303-e310. CA
  16. Paredes R, Tzou PL, van Zyl G, Barrow G, Camacho R, Carmona S, Grant PM, Gupta RK, Hamers RL, Harrigan PR, Jordan MR, Kantor R, Katzenstein DA, Kuritzkes DR, Maldarelli F, Otelea D, Wallis CL, Schapiro JM, Shafer RW. Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One. 2017 July 28;12(7):e0181357. CA
  17. Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, Toy J, Akagi L, Lima VD, Guillemi S, Montaner JSG, Barrios R. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS. 2017 June 19;31(10):1425-1434. CA
  18. St-Jean M, Harrigan PR, Sereda P, Montaner JS, Lima V. An assessment of the relationship between the World Health Organization HIV drug resistance early warning indicators and HIV drug resistance acquisition. HIV Medicine. 2017 May;18(5):342-353. CA
  19. Shkreta L, Blanchette M, Toutant J, Wilhelm E, Bell B, Story B, Balachandran A, Cochrane A, Cheung P, Harrigan PR, Grierson D, Chabot D. Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication. Nucleic Acids Research. 2017 April 20;45(7):4051-4067. CA
  20. Kesselring S, Cescon A, Colley G, Osborne C, Zhang W, Raboud J, Hosein S, Burchell A, Cooper C, Klein M, Loutfy M, Machouf N, Montaner JS, Rachlis A, Tsoukas C, Hogg R, Lima V; Canadian Observational Cohort Collaboration (CANOC). Quality of initial HIV care in Canada: extension of a composite programmatic assessment tool for HIV therapy. HIV Medicine. 2017 March;18(3):151-160.CA
  21. Leung J, Fishbane N, Jones M, Morin A, Xu S, Liu J, MacIsaac J, Milloy MJ, Hayashi K, Montaner JS, Horvath S, Kobor M, Sin D, Harrigan PR, Man S. Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion. Aging (Albany NY). 2017 February 23;9(3):687-705.CA
  22. Lima V, Wang L, Brumme C, Wu L, Montaner JS, Harrigan PR. Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification. PLoS One. 2017 February 2;12(2):e0171155. SA
  23. Rahimi A, Anmole G, Soto-Nava M, Escamilla-Gomez T, Markle T, Jin S, Lee G, Harrigan PR, Bangsberg D, Martin J, Avila-Rios S, Reyes-Teran G, Brockman M, Brumme Z. In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach. Journal of Virological Methods. 2017 February;240:32-41. CA
  24. Knox D, Anderson P, Harrigan PR, Tan D. Multidrug-resistant HIV-1 infection despite preexposure prophylaxis. New England Journal of Medicine. 2017 February 2;376(5):501-502. CA
  25. Gonzalez-Serna A, Swenson L, Watson B, Zhang W, Nohpal A, Auyeung K, Montaner JS, Harrigan PR. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure. Clinical Microbiology and Infection. 2016 December;22(12):1004.e9-1004.e16. SA
    Harris M, Ganase B, Watson B, Hull M, Guillemi S, Zhang W, Saeedi R, Harrigan PR. Efficacy and safety of “unboosting” atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF. HIV Clinical Trials. 2017 January;18(1):39-47. SA
  26. Penrose K, Wallis C, Brumme C, Hamanishi K, Gordon K, Viana R, Harrigan PR, Mellors J, Parikh U. Frequent cross-resistance to dapivirine in HIV-1 subtype C-infected individuals on failing first-line antiretroviral therapy in South Africa. Antimicrobial Agents and Chemotherapy. 2017 January 24;61(2). pii: e01805-16. CA
  27. Balachandran A, Wong R, Stoilov P, Pan S, Blencowe B, Cheung P, Harrigan PR, Cochrane A. Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation. Retrovirology. 2017 January 26. CA

 

Education

  • Ph.D. (Biochemistry), University of British Columbia, 1992
  • M.Sc. (Biochemistry), University of British Columbia, 1987
  • B.Sc.(Hons) (Biochemistry), University of British columbia, 1985

Comments are closed, but trackbacks and pingbacks are open.